Several oral β-blockers are US Food and Drug Administrationapproved for migraine prophylaxis, but their gradual absorption and modification by first-pass metabolism delays effective plasma levels for hours to days, limiting their use in acute migraines. 1 Timolol eyedrops provide a rapid route of delivery with the maximum plasma concentration achieved within 15 minutes of administration. 2, 3 This pharmacokinetic advantage supports a potential role for timolol eyedrops in managing acute migraine.
4,5
Methods | We conducted a randomized, crossover, placebocontrolled pilot study of timolol eyedrops as an abortive migraine treatment in adults. The study was approved by the institutional review board of the University of Missouri-Kansas City (Trial Protocol in the Supplement). Participants were recruited via our neurology and ophthalmology clinics, a listing on clinicaltrials.gov (NCT02630719), and flyers. Participants provided written consent. Men and women who were at least age 18 years and met the International Headache Society criteria for migraine with or without aura 6 were eligible for the study. All patients underwent a screening, which included complete neurological and ophthalmological examinations and a pregnancy test for women of childbearing potential. Participants were randomized to receive timolol maleate, 0.5%, or artificial tears at 1 drop in both eyes at onset and 30 minutes after. Participants were seen monthly for 5 visits over 4 months and crossed over at the 2-month mark with a 3-day washout period. A data sheet for each migraine instructed participants to rate their migraine attacks on a scale of 0 to 3 in terms of severity. At the conclusion of the study, the participants were also asked to rate the effectiveness of each drop on a scale of 1 to 4 to decide whether they would use the timolol in place of or in addition to current treatments. The aim of this pilot study was to determine the effect size of timolol on migraine headaches.
Results | A total of 198 migraine attacks were studied among 10 participants. The overall effectiveness of timolol was 2.4 compared with 1.4 with the placebo (Table) . Four participants found timolol highly effective compared with placebo while 1 participant found the opposite. The average percentage of headaches with a severity of none or mild at 2 hours was 57% with placebo compared with timolol (a Wilcoxon match paired test was conducted to account for repeated measurements and this difference was not found to be significant, with P = .26 as expected with a small pilot study). A 2-tailed χ 2 statistic suggests that 172 randomized participants or 86 crossover participants would be needed to power a study with α ≤ .05 and β ≤ 0.2. One participant developed a branch retinal artery occlusion while using placebo, which was believed to be unrelated to the study. No other adverse events, including hypotension or bradycardia, were observed. 
An Autopsy Case of Progressive Supranuclear Palsy With Incidental ATXN2 Expansion
A case of multiple system atrophy with predominant parkinsonism (MSA-P) with ATXN2 (OMIM 601517) expansion was previously reported. 1 However, the autopsy in that patient showed tauopathy without evidence of spinocerebellar ataxia type 2 (SCA2). Herein, we present the pathologic findings to correct the previous misdiagnosis. This patient is case 3 in the previous report, 1 which details clinical history and examination. He died when he was in his late 60s due to pneumonia, 9 years after onset of the disease. A rare chance to examine MSA-P with low-range ATXN2 expansion prompted us to perform an autopsy.
Methods | General autopsy was carried out with routine procedure. The time from death to the postmortem examination was 17 hours. The half brain was stored in a deep freezer (−80°C) and the remaining half brain was fixed in 10% neutral formalin for 4 weeks. After fixation, formalin-fixed paraffin embedded blocks were cut as 5-μm thickness. Hematoxylin-eosin, glial fibrillary acidic protein (1:200 dilution; Dako), phosphorylated tau (1:300 dilution AT8; ThermoFisher), 3 repeat tau (1: 40 000 dilution; Merck), 4 repeat tau (1:10 000 dilution; Millipore), α-synuclein (phospho S129, 1: 200 dilution; Abcam), phosphorylated TDP43 (1:10 000 dilution; Cosmo Bio), phosphorylated neurofilaments (1: 10 000 dilution; Milipore), NeuN (1:500 dilution; Milipore), and 1C2 (1:200 dilution; Milipore) immunohistochemistry and Luxol fast blue staining were carried out. Permission for autopsy was granted by the family, and the study was approved by the institutional review board of the Seoul National University Hospital.
Results | The weight of the fresh brain was 1450 g. Gross autopsy findings showed mild cortical atrophy with sulcus widening. Prominent pontine atrophy with cerebellar involvement was seen. The globus pallidus was atrophic. The putamen, caudate nucleus, and hippocampus were preserved. Depigmentation was observed in the substantia nigra and locus coeruleus. Microscopic examination showed widespread neuronal loss with reactive gliosis in the globus pallidus, subthalamic nucleus, substantia nigra, colliculi, periaqueductal gray matter, and the dentate nucleus of the cerebellum. Numerous tau-positive, ubiquitin-negative globose tangles, and tufted astrocytes were seen in the brainstem, thalamus, basal ganglia, hippocampus, cortex, cerebellum, and cervical spinal cord PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
-
To renew your protocol: 1. Complete this one-page form; 2. If necessary, update any sections of the protocol that need to be updated for the upcoming year (e.g., change in personnel, location) and attach any new supporting documents (e.g., other IRB approval letters); 3. Electronically "sign" the application by clicking in the check box on the "Obligations" page; 4. Remember to click "Submit Form" so that the IRB administrators receive your application. You must answer each question. Input N/A to answer any questions that are not applicable. NOTE: Documents that contain much of the information required to answer the participant number questions below can be found in the "Event History" section of each protocol. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
Description and number of any protocol deviations/violations or unanticipated problems (UPs)/adverse events (AEs), particularly those that may have affected the risks to subjects since the last approval date. 1 adverse event detailed in a separate report was an incidental branch retinal artery occlusion that occurred on the placebo arm of the study felt to be unrelated to the study. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
Were any additional research participants enrolled or data collected after the expiration date?
If Yes, describe all activities that continued including number of participants involved and any adverse event or incidents that occurred after expiration of approval.
NOTE: If renewal of the study does not occur before the expiration date of study approval ALL enrollment of participants and DATA COLLECTION must stop at the expiration date. Procedures and treatment needed for the safety of participants should continue but data collected during this time period CANNOT be used for research purposes.
6.
Informed Consent:
a. Does this study use a consent form? Y (if so please attach a copy of the previously approved "stamped" copy and a clean copy of the consent form)
7.
Has there been additional or new information about this study which may affect a subject's willingness to continue their participation, or that may need to be given to prior participants? (Such as safety information, complaints about the research, revised procedures, duration of study, recent literature, etc.) N If YES, please explain and describe how information was provided or is being provided to current or prior participants.
8.
If this is a multi-center trial, has the most recent data safety and monitoring report or other summary report been submitted to the IRB since the last review? N If No, submit a current report.
9.
Summarize all changes in the protocol since it was last approved (e.g., have you amended your protocol during the past year? This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
If necessary, proceed to the appropriate section(s) of the protocol and make your requested changes. Remember that if you are requesting to revise a document that is already attached, you must delete the already attached document and upload the revised document.
10. List of Protocol Sections (and questions) that have been changed/modified.
none.
- This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- Starred items indicate required fields whenever that section is completed.
For Expedited Review, all aspects of the research must include activities that (1) present no more than minimal risk to human subjects, and (2) involve one or more of the specific categories listed below.
Select the following applicable categories to determine if your research project qualifies under Expedited Review. If none of the categories are applicable to your research project, a Full Committee Review will be required. For Expedited or Full Review, proceed to complete the following application.If none of the expedited criteria are appropriate for your project, please move to the next screen WITHOUT checking any of these criteria; your protocol will be reviewed by the full IRB. Note: The IRB will make the final determination if your protocol is eligible for expedited review. ii) The medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.
2.
Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: a) From healthy, non-pregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or b) From other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.
3.
Prospective collection of biological specimens for research purposes by non-invasive means. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- h) Supra-and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; i) Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; j) Sputum collected after saline mist nebulization.
Collection of data through non-invasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)
Examples: a) Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
timolol eye drops in those suffering from acute migraine. This study will be a feasibility study for future research with the following aims: -To identify the efficacy of timolol drops on migraine symptoms -To identify effective recruitment and retention strategies for conducting a crossover designed migraine study on use of timolol eye drops versus placebo for acute treatment of migraine headaches. 
Purpose a)
Describe the purpose for the proposed project as well as the hypotheses/research questions to be examined. To determine differences in those treated with and without timolol eye drops at the onset of an acute migraine headache 1A: To explore differences in severity of symptoms 1B: To explore differences in duration of symptoms 1C: To explore differences in improvement of symptoms 1D: To explore differences in recurrence of symptoms 1E: To explore differences in the need for additional rescue medications to control symptoms 3. Background a) Relevant Background: Discuss the present knowledge, appropriate literature and rationale for conducting the research. Include the rationale for the selected subject population. According to the American Migraine Prevalence and Prevention study, migraine affects 29.5 million Americans[1]. Of those affected by migraine headache, 51% reported reduced work or school productivity; and, as the third leading cause of emergency room visits, migraine headache represents a significant burden for patients and healthcare systems [2, 3] . Unfortunately, available treatments for acute migraine are not always effective. Current home abortive therapies are limited to nonsteroidal anti-inflammatory medications, caffeine-containing preperations, intranasal lidocaine, isometheptene-containing mediations, intranasal dihydroergotamine and triptan medications [4] . Of these, triptan medications are considered the first line treatment for moderate to severe migraine headache and comprise 80% of prescribed migraine therapy [3] . However, the use of prescription medications, such as triptans and ergotamine, are limited in patients with ischemic heart disease, stroke, uncontrolled hypertension, and certain migraine subtypes. Cases of serotonin syndrome have also been reported with concurrent use of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors; and, the tendency for some prescription medications to trigger rebound headache also compromises management [4, 5] . These issues highlight the need for a PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
convenient abortive migraine home treatment that is both effective and fast-acting.
Oral beta-blockers, such as timolol and propranolol, are both FDA approved for migraine prophylaxis. However, their gradual absorption and modification by first pass metabolism delay effective plasma levels for hours to days, limiting their use in acute migraine [6] . However, timolol eye drops provide a rapid route of delivery, with max plasma concentration achieved within fifteen minutes of administration [7, 8] . This pharmacokinetic advantage presents a potential role for timolol eye drops in the management of acute migraine. With this route of administration, the well-known benefits of oral beta-blockers are be available to those with acute migraine headaches. Since 1980, multiple case reports have demonstrated a benefit of beta-blocker eye drops in acute migraine treatment. However to date, no prospective trials have been conducted [5] .
Since its approval by the FDA in 1978, timolol eye drops have remained a gold-standard treatment for glaucoma. The long-term and widespread use of beta-blocker eye drops demonstrate its tolerability, safety and high benefit to risk ratio. For those with migraine, this route of administration is easy, convenient, wellstudied and tolerated, inexpensive, and readily available. Beta-blocker eye drops may also be a more suitable option for those with co-existing vascular disease, severe nausea and vomiting or high-risk of rebound headache [5] . 
4.
Study Procedures (If this is a student project, the methods section of the thesis or dissertation proposal must be attached in section #16 -Attachment section.) a) Describe sequentially and in detail ALL procedures in which the research subjects will be involved. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ------------------------------------------------------------------------------------ per session, and duration or period of time over which the research will take place, etc. -For school-based research where class time is used, describe in detail the activities planned for nonsubjects and explain where both subjects and non-subjects will be located during the research activities. A complete medical history will be obtained II.A complete baseline ophthalmologic clinic examination within six months of study initiation II.A complete neurologic clinic examination prior to study initiation IIIII.Baseline heart rate and blood pressure measurements V.Pregnancy Test in any female of child-bearing age and potential VI. Subjects will then be randomly selected into a study group and control group. The Study group will receive Timolol eye drops. The control group will receive placebo salt-solution eye drop. They are to use their respective drops at the beginnings of an acute migraine. If they do not have relief after using the eye drop, they will proceed to use the usual medication regimen. VII: Subjects will maintain a migraine dairy that records time of headache onset or onset of headache recurrence. Each headache occurrence will be graded on a headache intensity rating based on a 4 point scale recommended by the IHS (0= no headache, 1= mild headache, 2=moderate headache, 3=severe headache). Also recorded for each headache will be the extent of functional impairment on a 4 point scale (0= function and work normally, 1=mild impairment, 2= severe impairment, 3=requiring bed rest), any associated symptoms (i.e. nausea, vomiting, photophobia, phonophobia), headache recurrences, use of any rescue medications, and adverse effects. At follow up visits, subjects will rate the overall effectiveness of the medication on a 4 point scale (0=poor, 1=fair, 2= good, 3=excellent). VII: Subjects will undergo interval clinical monitoring. This will include checking their migraine diaries, checking blood pressure and heart rate. VIII: After two months, all subjects in the study group will switch to the placebo group after a 3 day washout period and all subjects in the placebo group will switch to the study group after a three day washout period. The total study duration will be 4 months per patient. At the termination of the study, patients will fill out an "Exit survey" asking about how they would compare the two drops.
b)
Alternative Procedures. Describe alternative procedures, if any, that might be advantageous to the subject. Describe the important potential risks and benefits associated with the alternative procedure(s). Any standard treatment that is being withheld must be disclosed. This information must be included in the consent form.
No standard treatment will be withheld from the patient c) Will subjects be followed after their active participation is complete? Y PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
-------------------------------------------------------------------------------------
If yes, explain why and describe how:
Subjects will have undergone a neurological exam by TMC Neurologist, Dr. Gratton, who is willing to act as their neurology care provider after completion of the study if desired.
d)
Will subjects have access to the study treatment/procedure after completing the study? Y If yes, explain why and describe how:
If patients benefit from timolol eye drops for their migraine headaches and wish to continue using it as an abortive therapy, this will be an available option. e) Will subjects be audio recorded? N f) Will subjects be videotaped? N g) Will subjects be photographed? N (Explicit consent must be obtained for the use of any of these methods.) h) Study Endpoint. What are the guidelines or end points by which you can evaluate the alternative treatments during the study? If one treatment proves to be clearly more effective than another (or others) will the study be terminated before the projected total subject population has been enrolled? When will the study end if no important differences are detected? Interval efficacy analyses are not planned in this study. The study will enroll for approximately one year.
i) Describe the statistical methods of the research and plans for analysis of the data (i.e. planned statistics, justification of sample size, etc.). This study is intended to be an exploratory pilot study. Our goal is to enroll about 50 patients: 25 study-first patients and 25 control-first patients (each group will cross over at 2 months). Enrollment will take place for approximately one year. We will then work with a statistician to analyze our data, which include the migraine diary. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
---------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------
*
If yes, state which website(s):
clinicaltrials.gov If no, explain why not:
(If the study will be registered on ClinicalTrials.gov, the consent form must contain the required language about it.) This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
---------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------
These subjects meet the international headache society criteria for migraine headache. They suffer from recurrent migraine attacks and would most benefit from a convenient, well tolerated home therapy.
c)
If women, minorities, or minors are intentionally excluded, a clear compelling rationale must be provided. Examples for not including minors: disease does not occur in children; drug or device would interfere with normal growth and development; etc.
State if any of the subjects are students, employees, or laboratory personnel. They should be presented with the same written informed consent. If compensation is allowed, they should also receive it. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
X N/A ---------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------- Describe any planned screening procedures. Attach your screening document(s) (e.g., health history questionnaire) in the Attachment Section (#16). We will be performing complete ophthalmic and neurologic examinations on subjects prior to enrollment. Heart rate and blood pressure measurements will also be obtained and document prior to enrollment. Pregnancy tests will be administered to women of child bearing age and potential. Patients will be asked if there are any specific health concerns as established in our exclusion criteria g) Will bilingual or multilingual subjects be recruited? Y h) Will non-English speaking subjects be recruited? N If yes, state language(s) spoken (other than English): This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ---------------------------------------------------------------------------------- This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ------------------------------------------------------------------------------------ List any specific agencies or institutions that will provide access to prospective subjects. -Identify who will contact prospective subjects and how. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ---------------------------------------------------------------------------------- Note: Attach copies of ALL recruitment materials in the attachment Section This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ------------------------------------------------------------------------------------ Since receiving FDA approval in the 1970s, Timolol eye drops have been safely used as a standard treatment of glaucoma. Unintended side effects have been found to be generally mild and rare. Timolol eye drops may also cause localized eye irritation or decrease intraocular pressure. In susceptible patients, timolol eye drops may cause cardiovascular or pulmonary side effects. Subjects will be screened prior to enrollment to exclude those at risk, according to the current clinical standard of care. Extensive counseling of potential adverse reactions will be discussed with study participates c)
How will subjects be assessed for adverse events? Subjects will be monitored with scheduled clinical evaluations for the duration of the four month study. This will include intraocular pressure measurements, heart rate and blood pressure monitoring. Patients may also contact us by phone to address any questions or concerns.
d)
Is there a plan to monitor study data for subject safety? Y If yes, discuss who will monitor the study data and describe the monitoring plan: Subjects will be monitored with scheduled clinical evaluations. This will include intraocular pressure measurement, heart rate and blood pressure monitoring.
e)
Describe the procedures or safeguards in place to protect against or minimize potential risks (e.g., referral to psychological counseling resources). In addition to scheduled follow up examinations, subjects will be able to communicate with us throughout the study, and can let us know right away if they want to stop the study and are uncomfortable during clinical exam.
In the case of an adverse effect deemed severe by subject or investigator, the subject will be withdrawn from the study.
Discuss any potential direct benefits to subjects from their involvement in the project that would justify involvement of subjects in this study. This study may result in migraine symptom relief in subjects. There are no other direct benefits to the subject.
b) Discuss any potential indirect benefits to society that would justify involvement of subjects in this study. The knowledge and insights emanating from this study will potentially advance research efforts PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- ------------------------------------------------------------------------------------ surrounding acute migraine headache and ultimately may lead to better treatment of this condition.
c)
Briefly assess the risk/benefit ratio of the subject s participation. (Include consideration of alternative therapy, benefit to the class of patients, and benefits to society. Describe the subjects alternatives to participation in the study.) Since its approval by the FDA in 1978, timolol eye drops have remained a gold-standard treatment for glaucoma. The long-term and widespread use of beta-blocker eye drops demonstrate its tolerability, safety and high benefit to risk ratio. For those with migraine, this route of administration is easy, convenient, wellstudied and tolerated, inexpensive, and readily available. Beta-blocker eye drops may also be a more suitable option for those with co-existing vascular disease, severe nausea and vomiting or high-risk of rebound migraines.
---------------------------------------------------------------------------------------------
* * * Procedures to Maintain Confidentiality * * *
Procedures to Maintain Confidentiality a)
If information derived from the study will be provided to the subject's personal physician, a government agency, or any other person or group (other than the research team), describe to whom the information will be given and the nature of the information, if applicable. N/A b) Explain how you will protect subjects' privacy.Note: Privacy can be defined in terms of having control over the extent, timing, and circumstances of sharing oneself (physically, behaviorally, or intellectually) with others. Please keep this definition in mind as you respond to this item. To minimize the breach of confidentiality risk, we will not use the subject s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. the code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.
c)
Describe how you will maintain the confidentiality of subjects' information. Note: Confidentiality pertains to the treatment of information that an individual has disclosed in a relationship of trust and with the expectation that it will not be divulged to others (without permission) in ways that are inconsistent with the understanding of the original disclosure. Please keep this definition in mind as you respond to this item.
To minimize the breach of confidentiality risk, we will not use the subject s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
the list of subject names and corresponding unique study number in a secure, locked location. the code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.
d)
Who will have access to study records or specimens? (Please identify specific team members by name.) Sean Gratton MD and Ashley Abraham MD and Matthew Cossack MD and Eddy Nabrinski (UMKC Medical Student) e) Will data be collected anonymously (i.e., NO identifying information from subjects will be collected, recorded, or linked to the study data)? If not, please explain.
To minimize the breach of confidentiality risk, we will not use the subject s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. the code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.
f)
If you plan to use existing data, records or specimens, what is the source of the data/records/specimens, and how will you access them?NOTE: "Existing" means data or specimens collected (i.e., on the shelf) prior to the proposed research. It includes data or specimens collected for research and non-research activities. N/A g) Will subjects be asked to give permission for release of identifiable data (e.g.,information, videotapes), now or in future? If so, explain here and include appropriate statements in consent materials. No h) If using existing data/biological specimens, will the researchers have access to a code linking the data to personally identifiable information? N/A i) If identifying information will be collected and linked to data/specimens, explain at what stage identifiers will be removed from the data/specimens. If identifiers will be retained, explain why this is necessary and how confidentiality will be protected.
To minimize the breach of confidentiality risk, we will not use the subject s name or hospital number to identify them on any study records. Instead a unique study number will be assigned to each subject. Only this number will be used on study documents that relate to the subject. We will keep the list of subject names and corresponding unique study number in a secure, locked location. the PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
code used to protect subject confidentiality will be stored separately from other study related data. At the end of the project, this list will be destroyed.
j)
If the data is coded, explain where the key to identifiers will be stored, how it will be protected, and who will have access to it. The data will stored in a secure, locked location in the ophthalmology department. Only the research investigators will have access to the information. the code used to protect subject confidentiality will be stored separately from other study related data.
k) Explain why, where, in what format, and for how long data/specimens will be retained. Data storage must comply with UM System data <a href="http://www.umsystem.edu/ums/fa/management/records/guide/rrg01801"target="_blank"> retention and <a href="http://infosec.missouri.edu/classification/"target="_blank"> security policies. Please contact UMKC Information Services with questions (email: callcenter@umkc.edu, phone: 816-235-2000) . The data will be maintained on paper charts in a secure, locked location in the ophthalmology department The code used to protect subject confidentiality will be stored separately from other study related data. department. Records will be retained for seven (7) years after final report or project has been completed, then destroyed. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- - This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- If subjects are not able to give legal consent, explain how and from whom consent will be obtained. They will not be included in the study If consent is being obtained from non-English speaking subjects, explain the translation process for all documents seen by subjects, including consent documents. Describe the consent process in these circumstances. Non-English speakers will not be included in the study Note: Provide copies of translated and back-translated consent documentsand provide the translator s credentials. Translators must be certified or have proof of cultural competency education/training.) This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
- The HIPAA Privacy Rule establishes the right of an individual to authorize a covered entity, such as a health plan, health care clearinghouse or health care provider, to use and disclose his/her Protected Health Information (PHI) for research purposes. The Privacy Rule defines the elements of individual information that comprise PHI and establishes the conditions under which PHI may be used or disclosed by covered entities for research purposes. It also includes provisions to allow an individual's PHI to be disclosed or used in research without the person's authorization (i.e., IRB Waiver of HIPAA Requirement Authorization). Social Security numbers 3.
Telephone numbers 4.
All geographic subdivisions smaller than a State, including street address, city, county, precinct, zip code, and their equivalent geocodes, except for the initial three digits of a zip code, if, according to the PROTOCOL Expedited/Full Board Application UMKC This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
-- ----------------------------------------------------------------------------------- current publicly available data from the Bureau of the Census: (1) The geographic unit formed by combining all zip codes with the same three initial digits contains more than 20,000 people; and (2) The initial three digits of a zip code for all such geographic units containing 20,000 or fewer people is changed to 000 5.
All elements of dates (except year) for dates directly related to an individual, including birth date, admission date, discharge date, date of death; and all ages over 89 and all elements of dates (including year) indicative of such age, except that such ages and elements may be aggregated into a single category of age 90 or older 6.
Fax numbers 7.
Electronic mail addresses 8.
Medical record numbers 9.
Health plan beneficiary numbers 10.
Account numbers 11.
Certificate/license numbers 12.
Vehicle identifiers and serial numbers, including license plate numbers 13.
Device identifiers and serial numbers 14.
Web Universal Resource Locations (URLs) 15.
Internet Protocol (IP) address numbers 16.
Biometric identifiers, including finger and voice prints 17.
Full face photographic images and any comparable images; and 18.
Any other unique identifying number, character, or code (note this does not mean the unique code assigned by the Investigator(s) to code the research data) This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
---------------------------------------------------------------------------------------------
-- --------------------------------------------------------------------------------- Please be sure to attach all documents associated with your protocol. Failure to attach the files associated with the protocol may result in this protocol being returned to you for completion prior to being reviewed. Students: Be sure to attach the Methods section of your thesis or dissertation proposal. If this protocol is associated with a grant proposal, please remember to attach your grant. This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details.
-- --------------------------------------------------------------------------------- Provide all subjects a copy of the signed consent form, if applicable.
Modifications -Changes in any aspect of the study (for example, project design, procedures, consent forms, advertising materials, additional key personnel or subject population) will be submitted to the IRB for approval before instituting the changes.
Training -Human subject training certificates, including those for any newly added personnel, will be provided for all key personnel.Training must be updated every two (2) years.
